Paweł Winter

Dr. Paweł Winter

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AJAgnieszka Irena Jagiello-Gruszfeld
Agnieszka Irena Jagiello-Gruszfeld
MRMagdalena Rosińska
Magdalena Rosińska
MMMałgorzata Meluch
Małgorzata Meluch
KPKatarzyna Pogoda
Katarzyna Pogoda
ANAnna Niwinska
Anna Niwinska
ZNZbigniew I. Nowecki
Zbigniew I. Nowecki
Neoadjuvant systemic therapy has now become the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/− pertuzumab targeted therapy can improve the rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is considered a good prognostic factor, in particular, in patients with more aggressive breast cancer subtypes such as TNBC or HER2-positive cancers. Furthermore, most studies demonstrate that chemotherapy in combination with trastuzumab and pertuzumab is well tolerated. The retrospective analysis presented here concentrates on neoadjuvant therapy with the TCbH-P regimen, with a particular emphasis on patients over 60 years of age. We analysed the factors affecting the achievement of pCR and present the adverse effects of the applied therapies, opening discussion about optimizing the therapy of older patients with HER-2 positive breast cancer.

16 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
PWPaweł Winter
Paweł Winter
MFMalgorzata Fuksiewicz
Malgorzata Fuksiewicz
AJAgnieszka Jagiello-Gruszfeld
Agnieszka Jagiello-Gruszfeld
ZNZbigniew Nowecki
Zbigniew Nowecki
BKBeata Kotowicz
Beata Kotowicz
Purpose: To search for new predictive breast cancer biomarkers. We analyzed the serum concentrations of biomarkers involved in carcinogenesis, which can also be targeted by therapy. Methods: In a single-center prospective study, the serum levels of Aurora A, thymidine kinase 1, and human epidermal growth factor receptor type 3 (HER3) were determined in 119 women with BC before neoadjuvant treatment using ELISA kits. Results: The following clinical data were analyzed: age; TNM; the expression of ER, PGR, HER2, and Ki67; histological grade (G); and the response to neoadjuvant treatment (NAT) in the residual tumor burden classification (RCB). A complete pathological response (pCR) was achieved after NAT in 41 patients (34%). The highest proportion of the patients with a confirmed pCR was found for triple negative breast cancer (TNBC) (62.5%); non-luminal HER2-positive (52.6%) cancer subtypes (p = 0.0003); and in the G3 group (50%; p = 0.0078). The patients with higher levels of Aurora A were more likely to achieve pCR (p = 0.039). In the multivariate analysis, the serum Aurora A levels ≥ 4.75 ng/mL correlated with a higher rate of pCR (OR: 3.5; 95% CI: 1.2–10.1; p = 0.023). Conclusions: We showed that in a biologically heterogeneous group of BC patients, the pretreatment serum Aurora A levels were of significant value in predicting the response to NAT.

12 October 2023 in Polish Journal of Surgery
Verified
Journal Article
Closed access
AGAleksander Grous
Aleksander Grous
SMSlawomir Mazur
Slawomir Mazur
PWPaweł Winter
Paweł Winter
KKKrzysztof Kozak
Krzysztof Kozak
AJAgnieszka Irena Jagiello-Gruszfeld
Agnieszka Irena Jagiello-Gruszfeld
ZNZbigniew Nowecki
Zbigniew Nowecki
Introduction: The use of meshes in mastectomies with immediate breast reconstruction (IBR) has become the gold standard. Aim: The use of meshes in mastectomies with immediate breast reconstruction (IBR) has become a gold standard. The purpose of the study was to analyze the complications and own experience with the use of Serasynth fully absorbable and SeragynBR partially absorbable synthetic meshes. Material and methods: In the period from December 2017 to July 2020, 118 IBR were performed in the Author's Department with the use of SeragynBR and Serasynth meshes in 93 patients operated for breast cancer. 78 Serasynth meshes (Group 1) and 40 SeragynBR meshes (Group 2) were implanted. Results: The most common complication was persistent seroma collection, which was reported in 17.9% of cases in Group 1 and 25% in Group 2. Skin inflammation was reported in 7.6% and 17.5%, while infections in 2.5% and 5% of the operated breasts in Group 1 and Group 2. Reoperation was required in 5.1% and 5% of the patients in Group 1 and Group 2. The percentage of complications was lower when Serasynth rather than Seragyn BR meshes were implanted. The frequent incidence of the seroma collection did not contribute in any significant way to serious complications such as removal of mesh/implant or infection. The complications, which developed following the implantation of both mesh types, were similar to those presented in other publications concerning mastectomy with IBR with the use of synthetic meshes. The percentage of implant losses/explanations in the discussed groups was lower than that reported in the literature. Conclusion: Despite the complications, both types of meshes can be considered as safe additions to reconstructive breast surgeries. Level of Evidence: Level III.

12 January 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
AJAgnieszka Irena Jagiello-Gruszfeld
Agnieszka Irena Jagiello-Gruszfeld
MRMagdalena Rosińska
Magdalena Rosińska
MMMalgorzata Meluch
Malgorzata Meluch
KPKatarzyna Pogoda
Katarzyna Pogoda
ANAnna Niwińska
Anna Niwińska
ZNZbigniew I. Nowecki
Zbigniew I. Nowecki
Neoadjuvant systemic therapy has now become the the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/- pertuzumab targeted therapy can improve rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is considered a good prognostic factor, in particular in patients with more aggressive breast cancer subtypes such as TNBC or HER2 positive cancers. Furthermore, most studies demonstrate that chemotherapy in combination with trastuzumab and pertuzumab is well tolerated. The retrospective analysis presented here concentrates on neoadjuvant therapy with the TCbH-P regimen, with a particular emphasis on patients over 60 years of age. We analysed the factors affecting the achievement of pCR and presented adverse effects of the applied therapies, which opened a discussion about optimizing the therapy of older patients with HER-2 positive breast cancer.

11 March 2016 in European Urology Supplements
Verified
Journal Article
Closed access
AFA. Feber
A. Feber
PWPaweł Winter
Paweł Winter
PDP. Dhami
P. Dhami
MMM Martinez-Fernande
M Martinez-Fernande
DPDoru Paul
Doru Paul
JKJ. Kelly
J. Kelly

12 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
PWPaweł Winter
Paweł Winter
BKBeata Kotowicz
Beata Kotowicz
MFMalgorzata Fuksiewicz
Malgorzata Fuksiewicz
MKMaria Kowalska
Maria Kowalska
AJAgnieszka Jagiello-Gruszfeld
Agnieszka Jagiello-Gruszfeld
ZNZbigniew Nowecki
Zbigniew Nowecki
Further personalization is needed to improve the outcomes of breast cancer treatment. It is necessary to find new inexpensive and easily evaluated predictive markers. In this study, we determined serum level of Aurora A (AURKA), thymidine kinase 1 (TK1) and human epidermal growth factor receptor type 3 (HER3) by enzyme immunoassay ELISA. We collected peripheral blood sera of 119 women with breast cancer before neoadjuvant treatment and the control group of 47 randomly selected healthy women. After treatment we analyzed clinical data: age, initial TNM stage, tumor receptors expression: estrogen (ER), progesterone (PGR), epidermal growth factor receptor type 2 (HER2), Ki67, histological malignancy grade, biological subtype, and response to neoadjuvant treatment in residual cancer burden (RCB) classification. Pathologic complete response (PCR) was achieved in 41 patients (34.45%). In univariate analysis patients with higher AURKA levels were more likely to obtain PCR (p=0.039). In multivariate analysis we used the logit regression model with PCR as the dependent. The effect of AURKA concentration ≥4.75 ng / mL on the chance of achieving PCR was found (OR: 3.5; 95%CI: 1.2-10.1; p = 0.023). Other significant PCR factors included: node status (OR: 0.503; 95% CI: 0.263-0.965; p = 0.039), negative PGR expression (OR: 0.104; 95% CI: 0.038-0.284; p < 0.001), and Ki67 >20% (OR: 5.44; 95% CI: 1.24-23,9; p < 0.025). There was no significance in marker concentrations and clinical features nor between breast cancer patients and control group. The outcomes suggest that serum AURKA level is a potential PCR prediction marker in neoadjuvant breast cancer treatment. Further studies are needed to confirm our observations.